Floatz logo

59 assets in Rhabdomyosarcoma

Therapeutic assets addressing Rhabdomyosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ipilimumab
Rhabdomyosarcoma
Children's National Research InstituteP2BB (65)
Irinotecan
Rhabdomyosarcoma
Milton S. Hershey Medical CenterP2BB (64)
Adriamycin
Rhabdomyosarcoma
Children's National Research InstituteP2B (60)
Cyclophosphamide
Rhabdomyosarcoma
National Cancer Institute (NCI)P3B (60)
Dactinomycin
Rhabdomyosarcoma
Children's Oncology GroupP3B (60)
(+)-Vincristine
Rhabdomyosarcoma
Theodore LaetschP2B (60)
Vincristine Sulfate
Rhabdomyosarcoma
Children's Oncology GroupP3B (60)
Vinorelbine Ditartrate
Rhabdomyosarcoma
Children's Oncology GroupP3B (60)
Cis-Diamminedichloroplatinum Ii
Rhabdomyosarcoma
Fudan UniversityP2B (59)
Nivolumab
Rhabdomyosarcoma
Children's National Research InstituteP2B (59)
Olaparib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2B (57)
Palbociclib
Rhabdomyosarcoma
PfizerP2B (57)
PI3K/MTOR INHIBITOR LY3023414
Rhabdomyosarcoma
National Cancer Institute (NCI)P2B (57)
Tazemetostat
Rhabdomyosarcoma
National Cancer Institute (NCI)P2B (57)
Fludarabine
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (55)
Nogitecan
Rhabdomyosarcoma
PfizerP2CCC (55)
Vemurafenib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Ensartinib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Ivosidenib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Selpercatinib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Selumetinib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2CCC (53)
Isocyclophosphamide
Rhabdomyosarcoma
Fudan UniversityP2CCC (51)
Ivocizumab
Rhabdomyosarcoma
Fudan UniversityP2CCC (51)
L-Methionine
Rhabdomyosarcoma
St. Jude Children's Research HospitalP2CCC (51)
Onivyde
Rhabdomyosarcoma
St. Jude Children's Research HospitalP1/2CCC (48)
Peel-224
Rhabdomyosarcoma
Theodore LaetschP1/2CCC (48)
Talazoparib
Rhabdomyosarcoma
St. Jude Children's Research HospitalP1/2CCC (48)
Zoledronate
Rhabdomyosarcoma
University of FloridaP1/2CCC (48)
Surufatinib
Rhabdomyosarcoma
HutchmedP1/2CC (46)
Atezolizumab
Rhabdomyosarcoma
University of Texas Southwestern Medical CenterP1/2CC (43)
c7r-gd2.cart cells
Rhabdomyosarcoma
Baylor College of MedicineP1CC (43)
Cobolimab
Rhabdomyosarcoma
GlaxoSmithKlineP1/2CC (43)
Dostarlimab
Rhabdomyosarcoma
GlaxoSmithKlineP1/2CC (43)
Locnartecan
Rhabdomyosarcoma
National Cancer Institute (NCI)P1/2CC (43)
Silmitasertib
Rhabdomyosarcoma
Milton S. Hershey Medical CenterP1/2CC (43)
21.15.gpc3-car t cells
Rhabdomyosarcoma
Baylor College of MedicineP1C (39)
Anti-Egfr Antibody-Drug Conjugate Mrg003
Rhabdomyosarcoma
Sun Yat-sen UniversityP1C (39)
b7-h3 car t cells
Rhabdomyosarcoma
St. Jude Children's Research HospitalP1C (39)
Care T Cells
Rhabdomyosarcoma
Baylor College of MedicineP1C (39)
Catch T Cells
Rhabdomyosarcoma
Baylor College of MedicineP1C (39)
Cetuximab
Rhabdomyosarcoma
National Cancer Institute (NCI)P1C (39)
Edotreotide
Rhabdomyosarcoma
ITM Solucin GmbHP1C (39)
Fgfr4-Car T Cells
Rhabdomyosarcoma
National Cancer Institute (NCI)P1C (39)
Iopofosine (¹³¹I)
Rhabdomyosarcoma
Cellectar Biosciences, Inc.P1C (39)
Lifileucel
Rhabdomyosarcoma
Iovance Biotherapeutics, Inc.P1C (39)
Showing 1 to 50 of 59 assets
PreviousPage 1 of 2Next